[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"repetitive-transcranial-magnetic-stimulation-rtms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:repetitive-transcranial-magnetic-stimulation-rtms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,82,108,136,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100649569","repetitive-transcranial-magnetic-stimulation-for-people-with-etomidate-addiction-stop-e-rtms-x-etomidate-100649569",false,"NCT07736742","Repetitive Transcranial Magnetic Stimulation for People With Etomidate Addiction (SToP-E-rTMS x Etomidate)","Substance Misuse To Psychiatric Disorders for Etomidate -Repetitive Transcranial Magnetic Stimulation for People With Etomidate Addiction: a 6-month, Double-blind, Randomized, Sham-controlled Trial","SToP-E","Inclusion Criteria:\n\n* Able to read and communicate in English and\u002For Chinese\n* Able to give informed consent and\u002For able to provide an informed consent from the legal guardian (if applicable)\n* Using etomidate and\u002For its related analogues as the primary psychoactive substance of abuse\n* Suffering from etomidate addiction as defined by:\n\n  1. Etomidate Use Disorder classified under \"Sedative-, Hypnotic-, or Anxiolytic Use Disorder\" according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) with severity ≥ 1, or\n  2. Harmful Use or Dependence for etomidate classified under \"Mental and behavioral disorders due to use of sedatives or hypnotics\" according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), or\n  3. Hazardous use, harmful use or dependence classified under \"Hazardous use of sedatives, hypnotics or anxiolytics\" or \"Disorders due to use of sedatives, hypnotics or anxiolytics\" according to the Clinical descriptions and diagnostic requirements for International Classification of Diseases 11th Revision (ICD-11) mental, behavioral, and neurodevelopmental disorders.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Unable to read English or Chinese\n* Unable to give informed consent\n* Had been diagnosed with the following disorders including:\n\n  1\\. Neurodevelopmental Disorders:\n* DSM-5: Intellectual Disabilities, Communication Disorders, Specific Learning Disorder, Autism Spectrum Disorder and Motor Disorders\n* International Statistical Classification of Diseases and Related Health Problems 11th Revision (ICD-11): Disorders of intellectual development (6A00), Developmental speech or language disorders (6A01), Autism spectrum disorder (6A02), Developmental learning disorder (6A03), Developmental motor coordination disorder (6A04), Stereotyped movement disorder (6A06), Primary tics or tic disorders (8A05.0)\n* Other DSM-5 defined Substance Use Disorder greater than moderate in severity (i.e., severity score ≥4)\n* Neurocognitive Disorders (DSM-5, or ICD-11 6D70-72 \\& 6D80-86) 2. Contra-indicated to undergo rTMS:\n* with electronic and\u002For magnetic implants (e.g., pacemaker, implantable cardioverter defibrillator \\[ICD\\], cerebral shunts, cochlear implant, etc.)\n* with metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.)\n* pregnant\n* with any known or history of neurological conditions including cerebral vascular accidents (CVA), epilepsy, brain tumor or space occupying lesion, etc.\n* poorly controlled or unstable diabetes mellitus\n* receiving unstable dose(s) of antipsychotics, antidepressants, benzodiazepines and\u002For anticonvulsants in the past 3 months","ALL","18 Years","45 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if high-frequency rTMS works to treat etomidate addiction in adults. It will also learn about the safety and tolerability of rTMS. The main questions it aims to answer are:\n\n* Does active rTMS reduce craving, amount of etomidate use, frequency of etomidate use, and severity of etomidate use disorder?\n* Does active rTMS improve cognitive biases related to delayed reward discounting and risk sensitivity?\n* What side-effects do participants have when receiving rTMS?\n\nResearchers will compare active rTMS to sham rTMS to see if active rTMS works to treat etomidate addiction.\n\nParticipants will:\n\n* Receive active rTMS or sham rTMS over 4 weeks\n* Complete 20 rTMS sessions in total\n* Visit the clinic for treatment sessions and follow-up assessments\n* Complete assessments of etomidate use, craving, withdrawal symptoms, mood symptoms, cognition, and decision-making\n\nAttend follow-up assessments up to 6 months after baseline",[28,29],"Etomidate Use Disorder","Repetitive Transcranial Magnetic Stimulation (rTMS)",[31,32,33],"Etomidate","rTMS","addiction","NOT_YET_RECRUITING","2026-07-26",{"date":37,"type":38},"2026-07-30","ACTUAL",{"date":40,"type":22},"2026-09-01",{"date":42,"type":22},"2029-03-31",{"name":44,"class":45},"The University of Hong Kong","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100597125","repetitive-transcranial-magnetic-stimulation-combined-with-bimanual-therapy-for-upper-limb-stroke-rehabilitation-100597125","NCT07054424","Repetitive Transcranial Magnetic Stimulation Combined With Bimanual Therapy for Upper Limb Stroke Rehabilitation","Development of Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Machine-assisted Bimanual Therapy (BT) in Upper Limb Rehabilitation","Inclusion Criteria:\n\n1. Age 40-80 years;\n2. First-onset stroke patients;\n3. Patients diagnosed with cerebral infarction or hemorrhage through CT or MRI;\n4. Signed informed consent form by the patient and their family;\n5. Stable physiological parameters;\n6. Stroke occurred within the last 12 months;\n7. Patients with unilateral hand function impairment caused by the stroke;\n8. Upper limb muscle tone (Modified Ashworth Scale, MAS) less than 3 points;\n9. Able to follow two-step commands.\n\nExclusion Criteria:\n\n1. A history of epilepsy or family history of epilepsy;\n2. Presence of suicidal tendencies;\n3. Currently using medications that lower the seizure threshold;\n4. Pregnant or planning to become pregnant;\n5. Co-existing neurological diseases (such as multiple sclerosis, other neurodegenerative diseases, meningitis, brain abscess, or meningioma);\n6. Subjects with uncontrollable migraines caused by elevated intracranial pressure;\n7. Subjects taking antidepressants who cannot discontinue the medication;\n8. Subjects with sleep disorders during rTMS treatment;\n9. Subjects with cerebellar stroke or brainstem stroke;\n10. Cerebral ischemic disorders resulting from traumatic brain injury;\n11. Transient ischemic attacks (TIAs);\n12. History of bleeding tendency and other conditions affecting upper limb function, such as myasthenia gravis, systemic immune neuropathy, severe epilepsy, endocrine system disorders, wearers of external or internal cardiac pacemakers, individuals with metallic implants or orthopedic devices;\n13. Co-existing severe heart, liver, kidney dysfunction, or other serious physical illnesses;\n14. Subjects with impaired consciousness who cannot cooperate with examinations or treatments, such as those with mental disorders, or those with intellectual or cognitive impairments, severe dementia;\n15. Presence of implanted electronic devices in the body;\n16. Co-existing severe liver, kidney, or hematological disorders;\n17. Special vulnerable populations;\n18. Skin disease (e.g., pressure ulcers, trauma, cellulitis, etc.).","40 Years","80 Years",{"count":57,"type":22},54,[25],"The goal of this clinical trial is to evaluate whether combining repetitive transcranial magnetic stimulation (rTMS) with machine-assisted bimanual therapy (BT) can improve upper limb function in stroke patients. The participants will be individuals aged 40-80 years who have experienced a first-time ischemic or hemorrhagic stroke. The main questions it aims to answer are:\n\n* Does the combined therapy enhance motor recovery compared to traditional rehabilitation methods?\n* Are changes in brain activity associated with improvements in upper limb function?\n\nParticipants will be randomly assigned to different groups and will:\n\n* Receive rTMS stimulation on specific areas of the brain to modulate neural activity,\n* Perform machine-assisted bimanual exercises to promote motor skills, and\n* Undergo assessments before, immediately after, and during follow-up periods to measure functional improvements.",[61,29,62,63],"Post-stroke Upper Limb Hemiparesis","Bimanual Therapy","Neuromodulation",[65,66,32,67,68,69,70,71],"Stroke","neurorehabilitation","bimanual therapy","neuromodulation","upper limb function","theta burst stimulation","brain plasticity","RECRUITING","2026-06-10",{"date":75,"type":38},"2026-06-11",{"date":77,"type":38},"2025-06-05",{"date":79,"type":22},"2027-07-31",{"name":81,"class":45},"Chang Gung Memorial Hospital",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100621387","repetitive-transcranial-magnetic-stimulation-combined-with-language-training-for-language-disorders-in-children-with-global-developmental-delay-100621387","NCT07369960","Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Global Developmental Delay","Randomized Controlled Study for Repetitive Transcranial Magnetic Stimulation Combined With Language Training in Children With Language Disorders in Children With Global Developmental Delay","Inclusion criteria\n\n1. Children aged 2-5 years old, regardless of gender.\n2. Meet the diagnostic definition of GDD in China's Diagnostic Guidelines for Global Developmental Delay (2024), confirmed by Gesell Developmental Schedules (GDS). Language domain Developmental Quotient (DQ) ≤ 75. A DQ ≤ 75 is found in at least one of the four developmental domains: gross motor, fine motor, adaptive behavior, and personal-social conduct. Mild-moderate GDD is selected for the study.\n3. The presence of significant language developmental delay, the language ability is significantly lower than children of the same age and the same intellectual level, confirmed by the standardized scale of Sign-Significate Relations (S-S) assessment.\n4. The child is able to cooperate with the completion of rTMS treatment and language assessment and has no serious behavioral problems.\n5. Written informed consent obtained from the child's legal guardian. Exclusion Criteria\n\n1\\. History of epilepsy or convulsive seizures. 2. Having metal implants in the skull (e.g. aneurysm clips, metal stents, etc.) and electronic devices such as pacemakers and cochlear implants in the body.\n\n3\\. Other serious neurological conditions that may affect language function (e.g., cerebral palsy, progressive neurological disorders, etc.).\n\n4\\. Have a diagnosis of ASD. 5. Have a severe hearing or visual impairment. 6. Participation in other clinical trials that may affect speech function. 7. Skin lesions or infection at the scalp treatment site. 8. The fontanelle has not yet closed. 9. Previous rTMS treatment in the last 3 months. 10. Developmental quotient \\\u003C 40 in any developmental domains; other circumstances that prevented cooperation with the study.","2 Years","5 Years",{"count":92,"type":22},50,[25],"This study explores a safe and effective new approach to improve language function in children with Global Developmental Delay (GDD). Conducted at Xiangxi Autonomous Prefecture People's Hospital, the study will recruit approximately 50 children aged 2 to 5 years. Participants will be randomly assigned to one of two groups: one receiving personalized language training combined with non-invasive, painless repetitive Transcranial Magnetic Stimulation (rTMS) to activate language regions of the brain, and a control group receiving personalized training for comparative analysis. The study spans one month, including a two-week intervention period followed by a two-week follow-up to evaluate the efficacy and sustainability of the combined therapy. This study has been rigorously reviewed and approved by the hospital's Ethics Committee.",[96,29,97,98],"Developmental Delay Disorder","Global Developmental Delay","Language Disorders in Children","2026-05-28",{"date":101,"type":38},"2026-06-02",{"date":103,"type":22},"2026-05-27",{"date":105,"type":22},"2026-12-31",{"name":107,"class":45},"Xiangya Hospital of Central South University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":32,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100639308","repeated-transcranial-magnetic-stimulation-for-the-treatment-of-diarrhea-predominant-irritable-bowel-syndrome-a-randomized-clinical-trial-100639308","NCT07581756","Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Inclusion Criteria:\n\nEligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.\n\nExclusion Criteria:\n\nThe exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.","70 Years",{"count":117,"type":22},46,[25],"Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.\n\nDesign: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.",[121,122,29,123,124],"Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea (IBS-D)","Chronic Diarrhea","Intestinal Flora",[126,29],"Irritable Bowel Syndrome with diarrhea (IBS-D)","2026-05-06",{"date":129,"type":38},"2026-05-12",{"date":131,"type":38},"2024-12-01",{"date":133,"type":22},"2026-07-01",{"name":135,"class":45},"The First Affiliated Hospital of Soochow University",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":46},"100634991","high-frequency-repetitive-transcranial-magnetic-stimulation-for-cognitive-improvement-in-patients-with-post-stroke-cognitive-impairment-100634991","NCT07546877","High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment","Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Stroke Cognitive Impairment: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meets the diagnostic criteria for stroke as stipulated in the \"Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)\", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset;\n2. The disease course is 1-12 months;\n3. Has cognitive impairment (MoCA \\\u003C 26 points, education years ≤ 12 years, add 1 point to the score result);\n4. Age 35-75 years old, gender not limited;\n5. Stable vital signs, no progressive neurological symptoms;\n6. No severe aphasia, visual or auditory impairment, and able to complete the research protocol;\n7. Not using antidepressant drugs simultaneously;\n8. If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;\n9. Voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Has a history of brain tumors, brain trauma, epilepsy or mental disorders;\n2. Had cognitive impairment before the stroke;\n3. Underwent craniotomy or had a skull defect;\n4. Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);\n5. Has other serious diseases that may affect the study;\n6. Pregnant women","35 Years","75 Years",{"count":21,"type":22},[25],"To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.",[149,29,65],"Post-Stroke Cognitive Impairment (PSCI)",[151,152],"randomized controlled trials","double blind","2026-04-21",{"date":155,"type":38},"2026-04-23",{"date":157,"type":22},"2026-04-01",{"date":159,"type":22},"2027-07-01",{"name":161,"class":45},"Qilu Hospital of Shandong University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100589896","phase-1-efficacy-of-repeated-transcranial-magnetic-stimulation-combined-with-a-live-probiotic-tablet-combined-bifidobacterium-lactobacillus-enterococcus-and-bacillus-cereus-tablets-live-in-diarrhea-predominant-irritable-bowel-syndrome-ibs-d-100589896","NCT06960369","Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)","Inclusion Criteria:\n\n1. Must meet the diagnostic criteria for Irritable Bowel Syndrome of Rome IV.\n2. Age range between 18-70 years.\n3. The duration of the disease is more than 6 months.\n4. There are no pathologic abnormalities or biochemical changes that could explain the bowel-related symptoms.\n5. The IBS symptom severity score at baseline must not be less than 75.\n6. No pharmacological treatment (excluding emergency treatment) for IBS for at least 2 weeks prior to the start of treatment; no concurrent participation in other clinical programs.\n7. Voluntarily sign the relevant informed consent form and voluntarily participate in this clinical project.\n\nExclusion Criteria:\n\n1. Be less than 18 years old or more than 70 years old.\n2. Those who suffer from severe liver, kidney, hematopoietic system diseases, cardiovascular and cerebrovascular diseases, and psychiatric diseases that significantly affect cognitive function.\n3. Patients with clear organic diseases of the intestinal tract; patients with diabetes, hyperthyroidism and other systemic diseases that affect the digestive tract dynamics; patients who have had a history of surgery on the anus and intestines or the abdomen.\n4. The presence of the following conditions affecting the efficacy or safety judgment: ① regular use of preparations and drugs affecting gastrointestinal dynamics or function; ② treatment with other treatments and drugs that may affect the results of the judgment.\n5. Those who are pregnant, breastfeeding or less than 12 months after delivery.\n6. Patients with severe fear of needles, metal allergies or sensitivities, or those with pacemakers.\n7. Patients who do not comply with the randomized assignment to the treatment group or have a tendency to be unstable such as poor compliance.\n8. Patients who are participating in other research projects.\n9. Those who do not want to sign the informed consent form.",true,{"count":170,"type":22},400,[172],"PHASE1","To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)\n\nMethods:\n\nClinical efficacy evaluation of TMS combined with Live Probiotic tablet for chronic diarrhea in IBS patients. The 400 IBS patients who meet the recruitment criteria for the clinical study will be randomized into 100 patients in rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live), rTMS combined placebo, shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) and shamrTMS combined placebo group. Corresponding treatment was given for 2 week, rTMS group received 1 Hz\u002Fs, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz\u002Fs, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week. Clinical assessment included symptoms, stool traits, mood, and sleep.\n\n2\\. Study on the mechanism of using intestinal flora data to evaluate the treatment of chronic diarrhea in IBS patients. 30 cases each were included in the 4 groups of IBS-eligible patients, and repeated transcranial magnetic stimulation treatment was given to the patient group for 2 week, and the patient group underwent the assessment of investigating the quantity and metabolic changes of the intestinal flora in feces before and after the treatment.",[121,122,29,175,123,124],"Probiotic",[126,29,175],"2025-05-05",{"date":179,"type":38},"2025-05-07",{"date":131,"type":38},{"date":182,"type":22},"2026-06-01",{"name":135,"class":45}]